The Yin and Yang of regulatory T cells in infectious diseases and avenues to target them

Emmanuel Stephen-Victor1,2,3† | Iris Bosschem4† | Freddy Haesebrouck4 | Jagadeesh Bayry1,2,3,5

1 Institut National de la Santé et de la Recherche Médicale, Paris, France
2 Centre de Recherche des Cordeliers, Equipe—Immunopathologie et Immunointervention Thérapeutique, Paris, France
3 Sorbonne Universités, Université Pierre et Marie Curie, Paris, France
4 Department of Pathology, Bacteriology and Avian Diseases, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium
5 Université Paris Descartes, Sorbonne Paris Cité, Paris, France

Correspondence
Jagadeesh Bayry, Institut National de la Santé et de la Recherche Médicale, Unité 1138, Paris, France; or Centre de Recherche des Cordeliers, 15 Rue de l'Ecole de Médecine, Paris, F-75006, France.
Email: jagadeesh.bayry@crc.jussieu.fr

Funding information
Institut National de la Santé et de la Recherche Médicale (INSERM); Université Pierre et Marie Curie; Université Paris Descartes; Indo-French Center for Promotion of Advanced Research (CEFIPRA), Grant/Award Number: 4803-1

Abstract
CD4+CD25+FoxP3+ regulatory T cells (Tregs) are key players for maintaining immune tolerance and for reducing the inflammation-mediated tissue damage following infection. However, Tregs also suppress protective immune responses to pathogens (including virus, bacteria, parasites, and fungi) and vaccines and enhance pathogen persistence by inhibiting the activation and functions of both innate and adaptive immune cells such as dendritic cells, macrophages, and T and B lymphocytes and by promoting immunosuppressive environment. Therefore, equilibrium in the Treg number and function is important to ensure pathogen clearance and protection from infection-associated immunopathologies. Recent advances in understanding of Treg influence on the outcome of infection opened new avenues to target them. Various small molecules, pharmacological inhibitors, monoclonal antibodies that target Tregs provided proof of concept in experimental models. The field also benefits from advances in other subjects, particularly oncology and autoimmunity, where Treg-targeted therapies are exploited in the clinic to a greater extent. The future research should aim at translating this preclinical success to human application.

1 IMMUNE RESPONSE TO PATHOGENS

As a part of first line of defence, professional antigen-presenting cells (APCs) recognise pathogens via pathogen-associated molecular pattern (PAMP) and pattern-recognition receptor (PRR) interaction. PRR–PAMP interaction signals phagocytosis of antigens and their processing in endosomes and lysosomes for the presentation by major histocompatibility complex (MHC) class II to CD4+ T cells. Endogenous antigens are processed in proteasomes for the presentation by MHC I to CD8+ T cells. Signalling by PRR also leads to activation of APCs characterised by enhanced expression of costimulatory molecules to enhance T-cell activation, chemokines to guide migration of immune cells, and cytokines to mediate CD4+ T-cell polarization into effector Th1, Th2, and Th17 cells or various T suppressor cells including CD4+CD25+FoxP3+ regulatory T cells (Tregs). Suppressor T cells are diverse. In addition to classical Tregs, type 1 Tregs that express LAG3 and CD49b and secrete interleukin (IL)-10, transforming growth factor (TGF) β-producing Th3 cells, and CD8+ suppressor T cells are also identified. Among them, Tregs are most studied population and are the focus of this review.

Pathogens deploy several mechanisms to evade protective immune responses, and enhancement of immune suppressor mechanisms such as Tregs represents one of them. Although Tregs suppress protective immune responses and support persistence infection, they are also critical for reducing the inflammation-mediated tissue damage following infection (Figure 1). Therefore, equilibrium in the Treg number and function is important to ensure pathogen clearance and protection from infection caused immunopathologies.

2 CD4+CD25+FOXP3+ TREGS

Tregs are important for maintaining immune tolerance (Sakaguchi, Yamaguchi, Nomura, & Ono, 2008). In addition to thymus-derived
Tregs that are mostly self-antigen specific, Tregs can be induced in the periphery under the influence of cytokines and APCs. Induced Tregs are generally specific for foreign antigens and phenotypically similar to thymus-derived Tregs. However, thymus-derived Tregs are functionally stable. FoxP3 is the master regulator of Treg development and functions. In addition, Tregs constitutey express CTLA-4 and are CD127low. The other markers described on the Tregs are LAG-3, ICOS, GITR, CCR4, and neuropilin-1.

Current evidence suggests that Tregs can suppress most immune cells including CD4+ and CD8+ T cells, B cells, natural killer (NK) cells, NKT cells, and APCs such as dendritic cells (DCs), monocytes, and macrophages. Tregs inhibit proliferation and cytokines of effector T cells, promote B-cell anergy and impede antibody production, inhibit the expression of costimulatory molecules, antigen-presenting molecules, and inflammatory cytokines in APCs, and reduce their ability to stimulate T-cell responses. Tregs enhance tryptophan catabolism via IDO pathway and induce cytotoxic effects on target cells via perforin and granzymes. In addition, by consuming IL-2, Tregs hamper activation of effector T cells and promote apoptosis. Thus, Tregs affect all stages of immune response. Treg-mediated suppression of target cells implicates both soluble factors (TGF-β, IL-10, IL-35, perforins, and granzymes) and cell-associated molecules (CTLA-4, LAG-3, CD39, and neuropilin-1; Sakaguchi et al., 2008). One of the main mechanisms that underlie Treg expansion upon infection is direct modulation of APCs by pathogen or its PAMPs. In addition, direct stimulation of Tregs is also reported for certain PAMPs.

3 | TREGS IN BACTERIAL INFECTIONS: INHIBITION OF PROTECTIVE IMMUNE RESPONSES

Tregs are expanded in several chronic bacterial infections such as tuberculosis. Tuberculosis patients have increased Tregs both at the site of infection and in the circulation that compromise protective interferon (IFN)-γ responses (Guyot-Revol, Innes, Hackforth, Hinks, & Lalvani, 2006; Hougardy et al., 2007) and interfere with stasis of mycobacterial growth in macrophages (Semple et al., 2013; Figure 2). Detailed exploration in mice indicated that upon aerosol infection, expansion of Tregs occurs in the draining lymph nodes that defer the influx of effector CD4+ and CD8+ T cells to the lungs during early tuberculosis (Shafiani, Tucker-Heard, Kariyone, Takatsu, & Urdahl, 2010) and prevent bacilli clearance (Kursar et al., 2007; Scott-Browne et al., 2007).

Tregs also have role in the persistence of other chronic bacterial infections such as Mycobacterium leprae, Streptococcus pneumonia, and Salmonella (Johans, Ertelt, Rowe, & Way, 2010; Saini, Ramesh, & Nath, 2014; Zhang et al., 2011). In case of Helicobacter pylori, adequate Treg response although prevents peptic ulcer (Rad et al., 2006; Robinson et al., 2008), bacterial persistence leads to chronic inflammation and tumour induction. Tregs enhance susceptibility to prenatal pathogens wherein expansion of maternal Tregs predisposes to Listeria monocytogenes and Salmonella enterica and was dependent on IL-10 (Rowe, Ertelt, Aguilera, Farrar, & Way, 2011).

Tregs also influence clinical outcome of bacterial disease due to altered tissue distribution properties. Human challenge studies with Salmonella typhi showed that pathogen-specific upregulation of gut-homing integrin α4β7 on Tregs is important determinant of typhoid disease outcome (McArthur et al., 2015). Importantly, depletion of Tregs enhanced S. typhi-specific cytokine production by effector-memory CD8+ T cells in vitro.

In addition to expansion of Tregs, bacteria can enhance Treg migration at the site of infection by via chemokine axis such as CCL17/CCL22-CCR4 and CCL20-CCR6 axis (Cook et al., 2014; Wang, Sjolinder, Gao, Wan, & Sjolinder, 2016) and thus increasing the contact between them and target cells.

Bacteria stimulate Treg expansion by several mutually nonexclusive mechanisms. Mycobacterium tuberculosis-mediated Treg expansion in humans implicate PD-1-PD-L1/PD-L2 axis and COX-2-catalysed Prostaglandin E2 (PGE2) (Garg et al., 2008; Holla et al., 2016; Periasamy et al., 2011; Singh, Mohan, Dey, & Mitra, 2013; Trinath, Maddur, Kaveri, Balaji, & Bayry, 2012). Blockade of these pathways in vitro not only abrogated Treg expansion but also reciprocally enhanced IFN-γ responses (Periasamy et al., 2011; Singh et al., 2013; Stephen-Victor et al., 2015; Stephen-Victor et al., 2016). Additional pathways include Treg activation and expansion by bacteria-derived superantigens that directly link MHC class II on APCs and TCR on T cells (Taylor & Llewelyn, 2010) and MHC class II and PGE2-dependent Treg expansion by human colonic myofibroblasts (Pinchuk et al., 2011).

4 | TREGS IN VIRAL INFECTION: DISTINCT ROLES IN ACUTE VERSUS CHRONIC INFECTION

Initial studies in mice ascribed a role for Tregs in attenuating CD8 T-cell response to virus (Dittmer et al., 2004; Suvas, Kumaraguru, Pack, Lee, & Rouse, 2003). Tregs account for increased virus load by restraining IFN-γ responses from virus-specific CD8+ T cells in the...
Treg = regulatory T cell; MΦ = macrophage; Teff = effector T cells; Treg = regulatory T cell; B = B lymphocytes.

FIGURE 2 Various effects of regulatory T cells (Tregs) on innate and adaptive immune cells to suppress protective immune response to pathogens. DC = dendritic cells; MΦ = macrophage; Teff = effector T cells; Treg = regulatory T cell; B = B lymphocytes.

mouse reports demonstrated a role for Tregs in viral persistence and blunting immune response to other viruses including HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV). Various studies reported increased Tregs in lymphoid and mucosal tissues of HIV patients (Eppe et al., 2006; Nilsson et al., 2006). Furthermore, HIV can influence relocation of Tregs by inducing homing receptors CD62L and integrin α4β7 on Tregs (Ji & Cloyd, 2009). Tregs from lymphoid tissues of HIV patients had intact suppressive functions on HIV-specific T cells (Kinter et al., 2007) and in vitro depletion of Tregs from peripheral CD4+ T cells of HIV patients augmented anti-HIV responses (Weiss et al., 2004). Memory Tregs frequently express HIV coreceptor CCR5 and hence can accelerate HIV infection (Chachage et al., 2016). Low Treg frequencies are characteristics of elite HIV controllers and long-term nonprogressors, and reduced Treg numbers following therapy provide pointer towards success of antiretroviral therapy (Hunt et al., 2011; Montes et al., 2011; Piconi et al., 2010).

Increased frequency of circulating Tregs and diminished antigen-specific immune response are also reported in hepatitis patients (Cabrera et al., 2004; Stoop et al., 2005; Figure 2). HCV was reported to alter the functions of myeloid DCs to promote IL-10 production and to augment Treg expansion. Neutralizing IL-10 or depleting Tregs restored effector immune response (Hunt et al., 2011; Montes et al., 2011; Piconi et al., 2010).

Enhanced Tregs in chronic viral infections might be due to several mechanisms. Interaction of HIV-gp120 with CD4 on CD25+ Tregs favours Treg survival and Treg expansion (Ji & Cloyd, 2009). As in the case of bacteria, superantigen-mediated Treg expansion has been reported in chronic lymphocytic choriomeningitis virus (LCMV) infection (Punkosdy et al., 2014). Treg expansion could be also due to homology of viral peptide with human protein sequences as reported in HCV (Losikoff et al., 2015). Additionally, viruses can alter the functions of DCs to promote Tregs. Chronic HBV and HCV patients have enhanced IDO expression in the liver (Larrea et al., 2007). Importantly, IDO+ DCs differentiated from monocytes of HCV patients are potent inducers of Tregs and blocking IDO function significantly abrogates Treg generation from IDO+ DCs (Higashitani et al., 2013). Similarly, HIV also induces IDO expression in plasmacytoid DCs to promote Treg expansion (Manches et al., 2008).

A role for the coinhibitory molecules PD-1/PD-L1 in orchestrating Treg expansion and effectuating viral persistence has been suggested (Penaloza-MacMaster et al., 2014). Japanese encephalitis virus induces PD-L1 on monocyte-derived DCs to arbitrate Treg expansion and suppression of Th1 response (Gupta et al., 2014). PD-1 on Tregs also suppressed CD8+ T-cell responses in murine LCMV model via interaction with PD-L1 expressed on CD8+ T cells (Park et al., 2015).

In contrast to chronic infections, Tregs have beneficial role in acute viral infections and it goes beyond controlling excessive inflammation and immunopathology (Stross et al., 2012). Mucosal HSV infection in mice showed that Tregs are vital for the influx of NK cells, DCs, and T cells to the site of infection and hence for the early immune response (Lund, Hsing, Pham, & Rudensky, 2008). Treg-derived TGF-β helps in the maintenance of memory CD8 T-cell response to West Nile virus (Graham, Da Costa, & Lund, 2014). In the influenza model, Tregs enhance differentiation of virus-specific follicular T helper cells and hence germinal centre responses by controlling the availability of IL-2 (Leon, Bradley, Lund, Randall, & Ballesteros-Tato, 2014).

5 | TREGS AND PARASITIC INFECTION: FRIEND OR FOE?

Tregs benefiting persistence of parasite was first described in a mouse model of chronic Leishmania major infection. Tregs accumulate at the site of inoculation/infection and suppress protective Th1 response by both IL-10-dependent and -independent mechanisms (Belkaid, Piccirillo, Mendez, Shevach, & Sacks, 2002). Similarly, murine models of Plasmodium yoelii and Trypanosoma congolense have shown negative effects of Tregs towards T-cell response and eradication of parasites (Hisaeda et al., 2004; Okwor et al., 2012; Figure 2).

In humans, Plasmodium falciparum induces Tregs possibly by antigen nonspecific mechanism (implicating IL-2, IL-10, and TGF-β) that decreases antigen-specific immune response and promotes...
parasitaemia (Scholzen, Mittag, Rogerson, Cooke, & Plebanski, 2009; Walther et al., 2005). Further, TNFRII⁻ subset of Tregs with enhanced suppressor functions was proposed to contribute for the severity of malaria (Minigo et al., 2009). Of note, deficit in Tregs as observed in Fulani ethnic group has been attributed to lower susceptibility towards malaria (Torcia et al., 2008). All these studies suggest a detrimental role for Tregs in controlling parasitic infections.

Tregs have been implicated in disease reactivation as well. In Leishmania infection model, transfer of Tregs from infected mice into chronically infected mice resulted in the reactivation of disease (Mendez, Reckling, Piccirillo, Sacks, & Belkaid, 2004). In agreement with this, depletion of Tregs at the time of secondary challenge prevented disease reactivation (Mendez et al., 2004). Also, the frequencies of Tregs are higher in aged individuals and mice than their younger counterparts (Lages et al., 2008). Importantly, Tregs in aged mice spontaneously triggered the reactivation of chronic Leishmania infection (Lages et al., 2008).

As in the case of virus, Tregs do benefit host from parasite-associated inflammation and issue damage. In Schistosoma mansoni infection, dysregulated Th1, Th2, and Th17 response towards parasite or eggs is the leading cause of infection-associated liver and colon pathology and Tregs limit those responses (Baumgart, Tompkins, Leng, & Hesse, 2006; Herbert, Orekov, Perkins, & Finkelman, 2008; Taylor, Mohrs, & Pearce, 2006). More recently, it was demonstrated that Th17/Treg ratio was higher in Schistosoma haematobium-infected children with bladder pathology (Mbow et al., 2013). As Th17 and Tregs are reciprocally regulated, the higher Th17 response might have suppressed Treg generation leading to uncontrolled inflammation. Inability of Tregs to control sustained Th17-mediated inflammatory responses is also reported in lethal oral infection model of Toxoplasma gondii (Oldenhoeve et al., 2009).

Low level of parasite persistence in fact provides lifelong immunity to the host following reinfection. For example, mice that failed to completely eradicate the parasite were preimmune to subsequent infection. In contrast, mice that achieved sterile clearance were susceptible. By promoting persistence, Tregs exert a beneficial role in the maintenance of recirculating tissue-specific memory T cells that confer concomitant immunity (Belkaid et al., 2002).

6 | INTERPLAY BETWEEN TREGS AND FUNGAL INFECTIONS: MORE THAN COMMENSALISM MAINTENANCE

Of the diverse classes of pathogens that cause human diseases, fungal pathogens are the least characterised and often underappreciated. The main reason is that in healthy individuals, fungi stay as mostly commensal and Treg-mediated immune tolerance ensures fungal survival and commensalism at various parts of the body.

In a mouse model of disseminated candidiasis, Tregs suppress pro-inflammatory responses and enhance susceptibility to candidiasis. Toll-like receptor 2 (TLR2) can directly control the expansion and function of Tregs (Sutmuller et al., 2006), and the Treg frequencies and IL-10 production are lower in TLR2⁻/⁻ mice (Netea et al., 2004). Further, TLR2⁻/⁻ mice have enhanced Th1 response and are resistant to candida infections. In fact, neutralizing TLR2 in TLR2⁻/⁻ mice that receive wild-type Tregs is sufficient to reduce Candida infection (Sutmuller et al., 2006). These results suggest that Tregs employ TLR2 in effectuating immunosuppression during candida infections.

Interestingly, Tregs mediate a protective role during early phase of chronic mucocutaneous candidiasis wherein Th17 response plays a central role in the clearance of infection. By quenching IL-2, Tregs augment Th17 differentiation and the clearance of candida during acute phase of infection (Pandiyan et al., 2011). In contrast, Tregs exert a suppressive effect during later phases of infection (Pandiyan et al., 2011). Thus, depending on the timing of infection Tregs can effectuate differential immune response.

In the context of Aspergillus fumigatus, Tregs suppress both inflammatory and allergic response. During acute phase of infection, neutrophils are essential for initiating inflammation and resolution of infection. However, excessive reactive oxygen species and proteases released by neutrophils can contribute to lung pathology and the development of fungal sepsis. A division of labour occurs between distinct subsets of Tregs in controlling immunity and tolerance towards A. fumigatus. During early phase of infection, Tregs suppress innate cellular functions of neutrophils by contact-dependent (CTLA-4) and -independent (IL-10) mechanisms acting on IDO. During later phase of infection, Tregs coordinate suppression of allergic Th2 response via IL-10 and TGF-β (Montagnoli et al., 2006). Studies in human and murine cystic fibrosis support a role for IDO in balancing Th17 and Treg responses to A. fumigatus (Iannitti et al., 2013).

Treg-mediated suppression of pathological Th2 response that causes pulmonary injury is also observed in experimental Pneumocystis carinii and Cryptococcus neoformans infections (McKinley et al., 2006; Schulze et al., 2014). Mechanistically, Tregs used IRF4-dependent CCR5 to colocalise with Th2 cells in the lungs (Wiesner et al., 2016). Conversely, expansion of Tregs by administration of IL-2/anti-IL-2 complex during Cryptococcus infection reduced IgE production and decreased allergic airway inflammation (Schulze et al., 2016).

7 | COLONIC TREGS, COMMENSAL MICROBIOTA, AND GASTROINTESTINAL INFECTION

Compared to other organs, colon harbours higher proportion of Tregs (Atarashi et al., 2011; Round & Mazmanian, 2010). Approximately 30% of colonic CD4⁺ T cells express FoxP3. As these Tregs are helios⁺, majority of the studies suggest that colon Tregs are induced in nature (Atarashi et al., 2011). However, a case for thymus-derived Tregs in the colon has also been made (Cebra et al., 2013). As helios can be expressed in induced Tregs, and during activation and proliferation of T cells, the use of helios as a marker to distinguish induced and thymus-derived Tregs is questionable (Szurik et al., 2015). A substantial proportion of Tregs in the colon expresses RORγt, the lineage-specific transcription factor of Th17 cells (Sefik et al., 2015). Transcriptomic analysis of RORγt⁺FoxP3⁺ Tregs indicate that these cells display dual signatures of both Th17 and Treg cells (Yang et al., 2016). Importantly, Treg-specific signature markers such as FoxP3, CTLA-4, GITR, Eos, and Helios are significantly demethylated in
ROf"Fox3+ Tregs and hence represent stable Treg subset (Yang et al., 2016).

The commensal microbiota in the gut has a major influence in regulating Treg response in the intestine and in maintaining intestinal homeostasis. Although the gut encompasses diverse bacterial species, recent studies have identified specific bacteria that can induce Tregs in the colon. Clostridium species of the cluster IV and XIVa as well as Bacteroides fragilis were shown to induce IL-10-secreting Tregs in the colon (Atarashi et al., 2011; Round & Mazmanian, 2010). Further, by fermenting dietary fibres into small chain fatty acids such as acetate, butyrate, and propionate, commensal bacteria regulate Treg induction in the colon (Furusawa et al., 2013; Smith et al., 2013).

The induction of Tregs by microbiota regulates proinflammatory responses to gastrointestinal (GI) tract infections and hence suppresses infection-associated immunopathologies (Round & Mazmanian, 2009). However, an important question that needs to be addressed is whether one can harness the potential benefits of gut microbiota in treating GI tract infections by improving Treg number and functions. Some of the approaches include oral administration of prebiotics and probiotics. In addition, faecal microbial transplantation aiming at replenishing GI tract microbiota has shown great promise in treating Clostridium difficile infection (Gough, Shaikh, & Manges, 2011).

8 | TREGS DAMPEN IMMUNE RESPONSE TO VACCINES

Tregs inhibit intensity and duration of protective immunity to vaccines. Murine models have shown that Tregs suppress vaccine-generated primary and memory T-cell responses against viruses, bacteria, recombinant subunit, and DNA vaccines (Moore et al., 2005; Toka, Suvas, & Rouse, 2004). Human studies also suggest participation of Tregs in the suppression of immune response to vaccines (Wang, Tsai, Lei, Wang, & Liu, 2012).

9 | FUTURE DIRECTION: TARGETING TREGS IN INFECTIOUS DISEASES

As discussed earlier, although Tregs suppress protective immune responses, they are also important to control inflammation. Therefore, it may not be ideal to inhibit Tregs in acute infections as generated immune response normally sufficient to confine infection and Treg role in this scenario is more towards reducing the inflammation. On the other hand, chronic infection and vaccination represent ideal situations to block Treg activity to enhance protective immune responses.

9.1 | Potential strategies to block Tregs

9.1.1 | Elimination of Tregs

Treg depletion can enhance inflammation and autoimmunity, and hence transient depletion is desirable. Oncology field provides several options to deplete Tregs. Metronomic doses of cyclophosphamide transiently decrease Treg frequencies whereas T-cell effector functions are preserved, resulting in improved vaccine immunogenicity in human trials (Le & Jaffee, 2012). Daclizumab, a CD25 monoclonal antibody (MAb), has been approved for clinical use (Vincenti et al., 1998) and represents another way to improve immune response in chronic infections. This approach however has limitation as adverse effects (such as appearance of autoimmune response) were observed even in the experimental animals following CD25-based Treg depletion. In addition, this approach can eliminate CD25-expressing activated effector T cells and can reduce cytotoxic T-cell responses.

9.1.2 | Blocking molecules implicated in suppressive functions of Tregs

PD-1-PD-L1/PD-L2 pathway has a major role in the Treg biology. Inhibition of this pathway leads to enhanced IFN-γ response in vitro to M. tuberculosis (Periasamy et al., 2011; Singh et al., 2013; Stephen-Victor et al., 2015) and increased proliferative capacity of HIV-specific CD8+ T cells ex vivo (Peliger et al., 2015). Of note, blocking PD-1 pathway in combination with therapeutic LCMV vaccine synergistically augmented epitope-specific CD8+ T-cell response and accelerated viral clearance in mice (Ha et al., 2008). In macaques, in vivo PD-1 blockade increased simian immunodeficiency virus (SIV)-specific CD8+ T cells and enhanced the expansion of virus-specific CD4+ T cells and memory B cells culminating in better control of the virus and increased survival of SIV-infected macaques (Velu et al., 2009). Perturbing the PD-1-PD-L1 pathway also enhanced effector responses against HIV and other viruses (Trautmann et al., 2006). In view of encouraging results with therapeutic PD-1 MAbs in cancer, this approach could be undertaken along with anti-tuberculosis chemotherapy or anti-HIV therapy. However, it has to be noted that the PD-1 axis has a pivotal role in controlling immunopathology, therefore complete abrogation of this pathway can be detrimental. Inhibitors of CTLA-4 and Foxp3 represent additional ways to suppress Treg function (Ohkura, Hamaguchi, & Sakaguchi, 2011).

9.1.3 | Blocking chemokine receptors on Tregs

Human Tregs express CCR4 and promotes contact between Tregs and innate cells such as DCs that secrete CCR4 ligands leading to suppression of immune response. Because activation of DCs at the time of encounter with antigens determines the outcome of immune response, we proposed that reducing the impact of Tregs on DCs at this initial phase of immune response boosts the protective immune response to vaccines. To avoid adverse effects of Treg depletion, we targeted migration of Tregs by using small molecule antagonists to CCR4. In line with our hypothesis, CCR4 antagonists significantly enhanced cellular and humoral immune response to diverse vaccine antigens including Mycobacterium, Haematopinus suis, HBV, and Plasmodium (Bayry, Tartour, & Tough, 2014; Bayry et al., 2008; Bosschem et al., 2015; Davies et al., 2009). Tregs were not altered in these vaccinated animals, and signs of autoimmune response were also not observed.

A humanised CCR4 MAb mogamulizumab developed for the treatment of CCR4-expressing T-cell lymphomas has been shown to deplete Tregs (Sugiyama et al., 2013). Experimental model also reported enhanced anti-simian T-cell leukaemia virus type 1 immune responses upon CCR4 MAb administration (Sugata et al., 2016). Whether CCR4 MAbs enhance immune response in chronic infections remains to be explored.
Tregs are increased in AIDS patients and CCR5 expressed on Tregs has been implicated in the spread of HIV (Chachage et al., 2016). CCR5 antagonist Maraviroc in chronically HIV-1-infected patients reduced frequency and activation of Tregs (Pozo-Balado et al., 2014). This effect might be due to reduced viral loads and hence reduced signals for Treg activation.

9.1.4 | Blocking inducers of Tregs
Tregs are induced in the periphery by several molecules including TGF-β and PGE2. Therefore, targeting them provides options to inhibit Treg generation (Chen et al., 2015; Ohkura et al., 2011).

9.1.5 | In silico determination of Treg epitopes in vaccine antigens
The “computational vaccinology” aiming at mapping of epitopes and designing antigens devoid of Treg epitopes might help in reducing Treg response to vaccines and hence improve protective immune response (Moise et al., 2015).

9.2 | Potential strategies to boost Tregs
Tregs can be enhanced by numerous methods. Subinfectious exposure of pathogen can lead to Treg expansion as shown in the case of HCV in nonhuman primates (Park et al., 2013). Administrations of IL-2/anti-IL-2 complex, rapamycin, TGF-β, and sphingosine 1-phosphate receptor agonist are the additional ways to boost Treg response (Ohkura et al., 2011; Schulze et al., 2016).

10 | CONCLUSION
Recent advances in understanding of Treg influence on the outcome of infection opened new avenues to target them. Various small molecules, pharmacological inhibitors, and MAbs that target Tregs provided proof of concept in experimental models. The field also benefits from advances in other subjects, particularly oncology and autoimmunity, where Treg targeted therapies are exploited in the clinic to a greater extent. The future research should aim at translating this preclinical success to human application.

ACKNOWLEDGEMENTS
Due to space restrictions, we have included only the key references that in no way undermine the great value of uncited articles. This study is supported by Institut National de la Santé et de la Recherche Médicale (INSERM), Université Pierre et Marie Curie, Université Paris Descartes, and the Indo-French Center for Promotion of Advanced Research (CEFIPRA, grant 4803-1). ESV is a recipient of fellowship from CEFIPRA.

CONFLICT OF INTEREST
JB holds patent on small molecule CCR4 antagonists to target regulatory T cells in vaccination.

REFERENCES
Atarashi, K., Tanoue, T., Shima, T., Imaoka, A., Kuwahara, T., Momose, Y., ... Honda, K. (2011). Induction of colonic regulatory T cells by indigenous Clostridium species. Science, 331, 337–341.
Baumgart, M., Tompkins, F., Leng, J., & Hesse, M. (2006). Naturally occurring CD4+Foxp3+ regulatory T cells are an essential, IL-10-independent part of the immunoregulatory network in Schistosoma mansoni egg-induced inflammation. Journal of Immunology, 176, 5374–5387.
Bayry, J., Tourret, E., & Tough, D. F. (2014). Targeting CCR4 as an emerging strategy for cancer therapy and vaccines. Trends in Pharmacological Sciences, 35, 163–165.
Bayry, J., Chilian, E. Z., Davies, M. N., Forbes, E. K., Draper, S. J., Kaveri, S. V., ... Tough, D. F. (2008). In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination. Proceedings of the National Academy of Sciences of the United States of America, 105, 10221–10226.
Belkaid, Y., Piccirillo, C. A., Mendez, S., Shevach, E. M., & Sacks, D. L. (2002). CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature, 420, 502–507.
Bosschem, I., Bayry, J., De Bruyne, E., Van Deun, K., Smet, A., Vercauteren, G., ... Flahou, B. (2015). Effect of different adjuvants on protection and side-effects induced by Helicobacter suis whole-cell lystate vaccination. PLoS One, 10, e0131364.
Cabrera, R., Tu, Z., Xu, Y., Firpi, R. J., Rosen, H. R., Liu, C., & Nelson, D. R. (2004). An immunomodulatory role for CD4+CD25+ regulatory T lymphocytes in hepatitis C virus infection. Hepatology, 40, 1062–1071.
Cebula, A., Seweryn, M., Rempala, G. A., Pabla, S. S., McIndoe, R. A., Denning, T. L., ... Ignatowicz, L. (2013). Thymus-derived regulatory T cells contribute to tolerance to commensal microbiota. Nature, 497, 258–262.
Chachage, M., Pollakis, G., Kuffour, E. O., Haase, K., Bauer, A., Nadai, Y., ... Geldmacher, C. (2016). CD25+Foxp3+ memory CD4 T cells are frequent targets of HIV infection in vivo. Journal of Virology, 90, 8954–8967.
Chen, J. H., Perry, C. J., Tsui, Y. C., Staron, M. M., Parish, I. A., Dominguez, C. X., ... Kaech, S. M. (2015). Prostaglandin E2 and programmed cell death 1 signaling coordinately impair CTL function and survival during chronic viral infection. Nature Medicine, 21, 327–334.
Cook, K. W., Letley, D. P., Ingram, R. J., Staples, E., Skjoldmose, H., Atherton, J. C., & Robinson, K. (2014). CCL20/CCR6-mediated migration of regulatory T cells to the Helicobacter pylori-infected human gastric mucosa. Gut, 63, 1550–1559.
Davies, M. N., Bayry, J., Chilian, E. Z., Vani, J., Shaila, M. S., Forbes, E. K., ... Flower, D. R. (2009). Toward the discovery of vaccine adjuvants: Coupling in silico screening and in vitro analysis of antagonist binding to human and mouse CCR4 receptors. PLoS One, 4, e8084.
Dittmer, U., He, H., Messer, R. J., Schimmer, S., Olbrich, A. R., Ohlen, C., ... Hasenkrag, K. J. (2004). Functional impairment of CD8+ T cells by regulatory T cells during persistent retroviral infection. Immunity, 20, 293–303.
Dolganovic, A., Paek, E., Kodys, K., Thomas, J., & Szabo, G. (2008). Myeloid dendritic cells of patients with chronic HCV infection induce proliferation of regulatory T lymphocytes. Gastroenterology, 133, 2119–2127.
Epple, H. J., Loddenkemper, C., Kunkel, D., Troger, H., Maul, J., Moos, V., ... Schneider, T. (2006). Mucosal but not peripheral FOXP3+ regulatory T cells are highly increased in untreated HIV infection and normalize after suppressive HAART. Blood, 108, 3072–3078.
Furusawa, Y., Obata, Y., Fukuda, S., Endo, T. A., Nakato, G., Takahashi, D., ... Ohno, H. (2013). Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature, 504, 446–450.
Garg, A., Barnes, P. F., Roy, S., Quiroga, M. F., Wu, S., Garcia, V. E., ... Vankayalapati, R. (2008). Mannose-capped lipoarabinomannan- and prostaglandin E2-dependent expansion of regulatory T cells in human Mycobacterium tuberculosis infection. European Journal of Immunology, 38, 459–469.
Gough, E., Shaikh, H., & Manges, A. R. (2011). Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clinical Infectious Diseases, 53, 994-1002.

Graham, J. B., Da Costa, A., & Lund, J. M. (2014). Regulatory T cells shape immunity requires CD4+CD25+ regulatory T cells. American Journal of Respiratory and Critical Care Medicine, 193, 803–810.

Ha, S. J., Mueller, S. N., Wherry, E. J., Barber, D. L., Aubert, R. D., Sharpe, A. H., ... Ahmed, R. (2008). Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection. The Journal of Experimental Medicine, 205, 543–555.

Herbert, D. R., Orekov, T., Perkins, C., & Finkelman, F. D. (2008). IL-10 and TGF-beta redundantly protect against severe liver injury and mortality during acute schistosomiasis. Journal of Immunology, 181, 7214–7220.

Higashitani, K., Kanto, T., Kuroda, S., Yoshio, S., Matsuba, T., Kakita, N., ... Takehara, T. (2013). Association of enhanced activity of indoleamine 2,3-dioxygenase in dendritic cells with the induction of regulatory T cells in chronic hepatitis C infection. Journal of Gastroenterology, 48, 660–670.

Hisaeda, H., Maekawa, Y., Iwakawa, D., Okada, H., Himeno, K., Kishihara, K., ... Yasutomo, K. (2004). Escape of malaria parasites from host immunity requires CD4+CD25+ regulatory T cells. Nature Medicine, 10, 29–30.

Holla, S., Stephen-Victor, E., Prakhar, P., Sharma, M., Saha, C., Udupa, V., ... Balaji, K. N. (2016). Mycobacteria-reactive sonic hedgehog signaling mediates programmed death-ligand 1- and prostaglandin E2-induced regulatory T cell expansion. Scientific Reports, 6, 24193.

Hougary, J. M., Place, S., Hildebrand, M., Drowart, A., Debrée, A. S., Locht, C., ... Mascart, F. (2007). Regulatory T cells depress immune responses to both viral control and generalized immune activation in HIV control. The Journal of Immunology, 178, 205–212.

Huang, P. W., Landay, A. L., Sinclair, E., Martinson, J. A., Hatano, H., Emu, B., ... Kocisko, D. A., Kaveri, S. V. (2011). Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Journal of Virology, 85, 3390–3402.

Iannitti, R. G., Carvalho, A., Cunha, C., De Luca, A., Giovannini, G., Casagrande, A., ... Romani, L. (2013). TH17/Treg imbalance in murine cystic fibrosis is linked to indoleamine 2,3-dioxygenase deficiency but corrected by kynurenines. American Journal of Respiratory and Critical Care Medicine, 187, 609–620.

Ji, J., & Cloyd, M. W. (2009). HIV-1 binding to CD4 on CD4+CD25+ regulatory T cells enhances their suppressive function and induces them to home to, and accumulate in, peripheral and mucosal lymphoid tissues: An additional mechanism of immunosuppression. International Immunology, 21, 283–294.

Johanns, T. M., Ertelt, J. M., Rowe, J. H., & Way, S. S. (2010). Regulatory T cell suppressive potency dictates the balance between bacterial proliferation and clearance during persistent Salmonella infection. PLoS Pathogens, 6, e1000143.

Kinter, A., McNally, J., Riggins, L., Jackson, R., Roby, G., & Fauci, A. S. (2007). Suppression of HIV-specific T cell activity by lymph node CD25+ regulatory T cells from HIV-infected individuals. Proceedings of the National Academy of Sciences of the United States of America, 104, 3390–3395.

Kursar, M., Koch, M., Mittrucker, H. W., Nouailles, G., Bonhagen, K., Kamradt, T., & Kaufmann, S. H. (2007). Cutting edge: Regulatory T cells prevent efficient clearance of Mycobacterium tuberculosis. Journal of Immunology, 178, 2661–2665.

Lages, C. S., Suffia, I., Veillia, P. A., Huang, B., Warshaw, G., Hildeman, D. A., ... Chougnet, C. (2008). Functional regulatory T cells accumulate in aged hosts and promote chronic infectious disease reactivation. Journal of Immunology, 181, 1835–1848.

Larraea, E., Riez-Bouj, J. I., Gil-Guerrero, L., Casares, N., Aldabe, R., Sarobe, P., ... Prieto, J. (2007). Uprogulation of indoleamine 2,3-dioxygenase in hepatitis C virus infection. Journal of Virology, 81, 3662–3666.

Le, D. T., & Jaffee, E. M. (2012). Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: A current perspective. Cancer Research, 72, 3439–3444.

Leon, B., Bradley, J. E., Lund, F. E., Randall, T. D., & Ballesteros-Tato, A. (2014). FoxP3+ regulatory T cells promote influenza-specific Th2 responses by controlling IL-2 availability. Nature Communications, 5, 4395.

Losikoff, P. T., Mishra, S., Terry, F., Gutierrez, A., Ardito, M. T., Fast, L., ... Gregory, S. H. (2015). HCV epitope, homologous to multiple human protein sequences, induces a regulatory T cell response in infected patients. Journal of Hepatology, 62, 48–55.

Lund, J. M., Hsing, L., Pham, T. T., & Rudensky, A. Y. (2008). Coordination of early protective immunity to viral infection by regulatory T cells. Science, 320, 1220–1224.

Manches, O., Munn, D., Fallahi, A., Lifson, J., Chaperot, L., Plumas, J., & Bhardwaj, N. (2008). HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism. The Journal of Clinical Investigation, 118, 3431–3439.

Mbow, M., Larkin, B. M., Meurs, L., Wammes, L. J., de Jong, S. E., Labuda, L. A., ... Yazdanbakhsh, M. (2013). T-helper 17 cells are associated with pathology in human schistosomiasis. The Journal of Infectious Diseases, 207, 186–195.

McArthur, M. A., Fresnay, S., Magder, L. S., Darton, T. C., Jones, C., Waddington, C. S., ... Szein, M. B. (2015). Activation of Salmonella Typhi-specific regulatory T cells in typhoid disease in a wild-type S. Typhi challenge model. PLoS Pathogens, 11, e1004914.

Mckinley, L., Logar, A. J., McAllister, F., Zheng, M., Steele, C., & Kolls, J. K. (2006). Regulatory T cells dampen pulmonary inflammation and lung injury in an animal model of pneumocystis pneumonia. Journal of Immunology, 177, 6215–6226.

Mendez, S., Reckling, S. K., Piccirillo, C. A., Sacks, D., & Belkaid, Y. (2004). Role for CD4+CD25+ regulatory T cells in reactivation of persistent leishmaniasis and control of concomitant immunity. The Journal of Experimental Medicine, 200, 201–210.

Minigo, G., Woodberry, T., Piera, K. A., Salwati, E., Tió, E., Kenangalem, E., ... Pieblans, M. (2009). Parasite-dependent expansion of TNF receptor II-positive regulatory T cells with enhanced suppressive activity in adults with severe malaria. PLoS Pathogens, 5, e1000402.

Moise, L., Gutierrez, A., Kibria, F., Martin, R., Tassone, R., Liu, R., ... De Groot, A. S. (2015). iVAX: An integrated toolkit for the selection and optimization of antigens and the design of epitope-driven vaccines. Human Vaccines & Immunotherapeutics, 11, 2312–2321.

Montagnoli, C., Fallarino, F., Gazzano, R., Bozza, S., Belloccchio, S., Zelante, T., ... Romani, L. (2006). Immunity and tolerance to Aspergillus involve functionally distinct regulatory T cells and tryptophan catabolism. Journal of Immunology, 176, 1712–1723.

Montes, M., Sanchez, C., Lewis, D. E., Grass, E. A., Aardvark, Z., & White, A. C. J. (2011). Normalization of FoxP3+ regulatory T cells in response to effective antiretroviral therapy. The Journal of Infectious Diseases, 203, 496–499.

Moore, A. C., Gallimore, A., Draper, S. J., Watkins, K. R., Gilbert, S. C., & Hill, A. V. (2005). Anti-CD25 antibody enhancement of vaccine-induced immunogenicity: Increased durable cellular immunity with reduced immunodominance. Journal of Immunology, 175, 7264–7273.

Netea, M. G., Suttmuller, R., Hermann, C., Van der Graaf, C. A., Van der Meer, J. W., van Krieken, J. H., ... Kullberg, B. J. (2004). Toll-like receptor 2 suppresses immunity against Candida albicans through induction of IL-10 and regulatory T cells. Journal of Immunology, 172, 3712–3718.

Nilsson, J., Boasso, A., Veillia, P. A., Zhang, R., Vaccari, M., Fanchini, G., ... Chougnet, C. (2006). HIV-1-driven regulatory T cell accumulation in...
lymphoid tissues is associated with disease progression in HIV/AIDS. Blood, 108, 3808–3817.

Ohkura, N., Hamaguchi, M., & Sakaguchi, S. (2011). FOXP3+ regulatory T cells: Control of FOXP3 expression by pharmacological agents. Trends in Pharmacological Sciences, 32, 158–166.

Okwor, I., Onyilagha, C., Kuriakose, S., Mou, Z., Jia, P., & Uzonna, J. E. (2012). Regulatory T cells enhance susceptibility to experimental Trypanosoma conglense infection independent of mouse genetic background. PLoS Neglected Tropical Diseases, 6, e1761.

Oldenhove, G., Bouladoux, N., Wohlfert, E. A., Hall, J. A., Chou, D., Dos Santos, L., ... Belkaid, Y. (2009). Decrease of Foxp3+ Treg cell number and acquisition of effector cell phenotype during lethal infection. Immunity, 31, 772–786.

Pandian, P., Conti, H. R., Zheng, L., Peterson, A. C., Mathern, D. R., Hernandez-Santos, N., ... Lenardo, M. J. (2011). CD4+CD25+Foxp3+ regulatory T cells promote Th17 cells in vitro and enhance host resistance to mouse Candida albicans Th17 cell infection model. Immunity, 34, 422–434.

Park, H. J., Park, J. S., Jeong, Y. H., Son, J., Ban, Y. H., Lee, B. H., ... Ha, S. J. (2015). PD-1 upregulated on regulatory T cells during chronic virus infection enhances the suppression of CD4+ T cell immune response via the interaction with PD-L1 expressed on CD4+ T cells. Journal of Immunology, 194, 5801–5811.

Park, S. H., Veerapu, N. S., Shin, E. C., Biancotto, A., McCoy, J. P., Capone, S., ... Rehemann, B. (2013). Subinfectious hepatitis C virus exposures suppress T cell responses against subsequent acute infection. Nature Medicine, 19, 1638–1642.

Pellegro, C., Argilaguet, J., Guerri-Fernandez, R., Torres, B., Ligero, C., Colomer, P., ... Meyerhans, A. (2015). PD-L1 blockade differentially impacts regulatory T cells from HIV-infected individuals depending on plasma viremia. PLoS Pathogens, 11, e1005270.

Penaloza-MacMaster, P., Kamphorst, A. O., Wieland, A., Araki, K., Iyer, S. S., ... Ahmed, R. (2014). Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection. The Journal of Experimental Medicine, 211, 1905–1918.

Periasamy, S., Dhiman, R., Barnes, P. F., Paidipally, P., Tvninnereim, A., Bandaru, A., ... Vankayalapati, R. (2011). Programmed death 1 and cytokine inducible SH2-containing protein dependent expansion of regulatory T cells upon stimulation with Mycobacterium tuberculosis. The Journal of Infectious Diseases, 203, 1256–1263.

Piconi, S., Trabattoni, D., Gori, A., Parisotto, S., Magni, C., Meraviglia, P., ... Clerici, M. (2010). Immune activation, apoptosis, and Treg activity are associated with persistently reduced CD4+ T-cell counts during antiretroviral therapy. AIDS, 24, 1991–2000.

Pinchuk, I. V., Beswick, E. J., Saada, J. I., Boya, G., Schmitt, D., Raju, G. S., ... Powell, D. W. (2011). Human colonic myofibroblasts promote expansion of CD4+ CD25high Foxp3+ regulatory T cells. Gastroenterology, 140, 2019–2030.

Pozo-Balado, M. M., Martinez-Bonet, M., Rosado, I., Ruiz-Mateos, E., Mendez-Lagares, G., Rodriguez-Mendez, M. M., ... Leal, M. (2014). Maraviroc reduces the regulatory T-cell frequency in antiretroviral-naive HIV-infected subjects. The Journal of Infectious Diseases, 210, 890–898.

Punkosdy, G. A., Blain, M., Glass, D. D., Lozano, M. M., O’Mara, L., Dudley, J. P., ... Shevach, E. M. (2011). Regulatory T-cell expansion during chronic viral infection is dependent on endogenous retroviral superantigens. Proceedings of the National Academy of Sciences of the United States of America, 108, 3677–3682.

Rad, R., Brenner, L., Bauer, S., Schwendy, S., Layland, L., da Costa, C. P., ... Prinz, C. (2006). CD25+Foxp3+ T cells regulate gastric inflammation and Helicobacter pylori colonization in vivo. Gastroenterology, 131, 525–537.

Robinson, K., Kenehefek, R., Pidgeon, E. L., Shakib, S., Patel, S., Polson, R. J., ... Atherton, J. C. (2008). Helicobacter pylori-induced peptic ulcer disease is associated with inadequate regulatory T cell responses. Gut, 57, 1375–1385.

Round, J. L., & Mazmanian, S. K. (2009). The gut microbiota shapes intestinal immune responses during health and disease. Nature Reviews. Immunology, 9, 313–323.

Round, J. L., & Mazmanian, S. K. (2010). Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proceedings of the National Academy of Sciences of the United States of America, 107, 12204–12209.

Rowe, J. H., Ertelt, J. M., Aguiera, M. N., Farrar, M. A., & Way, S. S. (2011). Foxp3+ regulatory T cell expansion required for sustaining pregnancy hormone defense against prenatal bacterial pathogens. Cell Host & Microbe, 10, 54–64.

Saini, C., Ramesh, V., & Nath, I. (2014). Increase in TGF-beta secreting CD4+CD25+ FOXP3+ T regulatory cells in anergic lepromatous leprosy patients. PLoS Neglected Tropical Diseases, 8, e2639.

Sakaguchi, S., Yamaguchi, T., Nomura, T., & Ono, M. (2008). Regulatory T cells and immune tolerance. Cell, 133, 775–787.

Scholzen, A., Mittag, D., Rogerson, S. J., Cooke, B. M., & Plebanski, M. (2009). Plasmid falciparum-mediated induction of human CD25Foxp3 CD4 T cells is independent of direct TCR stimulation and requires IL-2, IL-10 and TGFbeta. PLoS Pathogens, 5, e1000543.

Schulze, B., Piehler, D., Eschke, M., Heyen, L., Protschka, M., Kohler, G., & Alber, G. (2016). Therapeutic expansion of CD4+Foxp3+ regulatory T cells limits allergic airway inflammation during pulmonary fungal infection. Pathogens and Disease, 74, ftw020.

Schulze, B., Piehler, D., Eschke, M., von Buttllar, H., Kohler, G., Sparwasser, T., & Alber, G. (2014). CD4+Foxp3+ regulatory T cells suppress fatal helper 2 cell immunity during pulmonary fungal infection. European Journal of Immunology, 44, 3596–3604.

Scott-Browne, J. P., Shafiani, S., Tucker-Heard, G., Ishida-Tsutoba, K., Fontenot, J. D., Rudensky, A. Y., ... Udahl, K. B. (2007). Expansion and function of Foxp3-expressing T regulatory cells during tuberculosis. The Journal of Experimental Medicine, 204, 2159–2169.

Sefik, E., Geva-Zatorsky, N., Oh, S., Konnikova, L., Zemmour, D., McGuire, A. M., ... Benoist, C. (2015). MUCOSAL IMMUNOLOGY. Individual intestinal symbionts induce a distinct population of ROtreg+ regulatory T cells. Science, 349, 993–997.

Semple, P. L., Binder, A. B., Davids, M., Maredza, A., van Zyl-Smit, R. N., & Dheda, K. (2013). Regulatory T cells attenuate mycobacterial stasis in alveolar and blood-derived macrophages from patients with tuberculosis. American Journal of Respiratory and Critical Care Medicine, 187, 1249–1258.

Shafiani, S., Tucker-Heard, G., Kariyone, A., Takatsu, K., & Udahl, K. B. (2010). Pathogen-specific regulatory T cells delay the arrival of effector T cells in the lung during early tuberculosis. The Journal of Experimental Medicine, 207, 1409–1420.

Singh, A., Mohan, A., Dey, A. B., & Mitra, D. K. (2013). Inhibiting the programmed death 1 pathway rescues Mycobacterium tuberculosis-specific interferon gamma-producing T cells from apoptosis in patients with pulmonary tuberculosis. The Journal of Infectious Diseases, 208, 603–615.

Smith, P. M., Howitt, M. R., Panikov, N., Michaud, M., Gallini, C. A., Bohlooly, Y. M., ... Garrett, W. S. (2013). The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science, 341, 569–573.

Stephen-Victor, E., Saha, C., Sharma, M., Holla, S., Balaji, K. N., Kaveri, S. V., & Bayry, J. (2015). Inhibition of programmed death 1 ligand 1 on dendritic cells enhances Mycobacterium-mediated interferon γ (IFN-γ) production without modulating the frequencies of IFN-γ-gamma-producing CD4+ T cells. The Journal of Infectious Diseases, 211, 1027–1029.

Stephen-Victor, E., Sharma, V. K., Das, M., Karnam, A., Saha, C., Lecerf, M., ... Bayry, J. (2016). IL-1β but not programmed death-1 and programmed death-ligand pathway is critical for the human Th17 response to Mycobacterium tuberculosis. Frontiers in Immunology, 7, 465.
Stoop, J. N., van der Molen, R. G., Baan, C. C., van der Laan, L. J., Kuipers, E. J., Kusters, J. G., & Janssen, H. L. (2005). Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology, 41, 771–778.

Stross, L., Gunther, J., Gasteiger, G., Asen, T., Graf, S., Aichler, M., ... Protzer, U. (2012). Foxp3+ regulatory T cells protect the liver from immune damage and compromise virus control during acute experimental hepatitis B virus infection in mice. Hepatology, 56, 873–883.

Sugiyama, D., Nishikawa, H., Maeda, Y., Nishioka, M., Tanemura, A., Nosaka, K., ... Matsuoka, M. (2016). Enhancement of anti-STLV-1/HTLV-1 immune responses through multimodal effects of anti-CCR4 antibody. Scientific Reports, 6, 27150.

Sugiyama, D., Nishikawa, H., Maeda, Y., Nishioka, M., Tanemura, A., Katayama, I., ... Sakaguchi, S. (2013). Anti-CCR4 mAb selectively depletes effector-type Foxp3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proceedings of the National Academy of Sciences of the United States of America, 110, 17945–17950.

Suttmuller, R. P., den Brok, M. H., Kramer, M., Bennink, E. J., Toonen, L. W., Kullberg, B. J., ... Adema, G. J. (2006). Toll-like receptor 2 controls expansion and function of regulatory T cells. The Journal of Clinical Investigation, 116, 485–494.

Suvas, S., Kumaraguru, U., Pack, C. D., Lee, S., & Rouse, B. T. (2003). CD4+ CD25+ T cells regulate virus-specific primary and memory CD8+ T cell responses. The Journal of Experimental Medicine, 198, 889–901.

Szurek, E., Cebula, A., Wojciech, L., Pietrzak, M., Rempala, G., Kisielow, P., & Ignatowicz, L. (2015). Differences in expression level of Helios and Neuropilin-1 do not distinguish thymus-derived from extrathymically-induced CD4+Foxp3+ regulatory T cells. PLoS One, 10, e0141161.

Taylor, A. L., & Llewelyn, M. J. (2010). Superantigen-induced proliferation of human CD4+CD25+ T cells is followed by a switch to a functional regulatory phenotype. Journal of Immunology, 185, 6591–6598.

Taylor, J. J., Mohrs, M., & Pearce, E. J. (2006). Regulatory T cell responses develop in parallel to Th responses and control the magnitude and phenotype of the Th effector population. Journal of Immunology, 176, 5839–5847.

Toka, F. N., Suvas, S., & Rouse, B. T. (2004). CD4+CD25+ T cells regulate vaccine-generated primary and memory CD8+ T-cell responses against herpes simplex virus type 1. Journal of Virology, 78, 13082–13089.

Torría, M. G., Santarlasci, V., Cosmi, L., Clemente, A., Maggi, L., Mangano, V. D., ... Modiano, D. (2008). Functional deficit of T regulatory cells in Fulani, an ethnic group with low susceptibility to Plasmodium falciparum malaria. Proceedings of the National Academy of Sciences of the United States of America, 105, 646–651.

Trautmann, L., Janbazian, L., Chomont, N., Said, E. A., Gimign, S., Bessette, B., ... Sekaly, R. P. (2006). Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nature Medicine, 12, 1198–1202.

Trinath, J., Maddur, M. S., Kaveri, S. V., Balaji, K. N., & Bayry, J. (2012). Mycobacterium tuberculosis promotes regulatory T-cell expansion via induction of programmed death-1 ligand 1 (PD-1, CD274) on dendritic cells. The Journal of Infectious Diseases, 205, 694–696.

Veli, V., Titaqji, K., Zho, B., Husain, S., Pldavega, A., Lai, L., ... Amara, R. R. (2009). Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature, 458, 206–210.

Vincenti, F., Kirkman, R., Light, S., Bumgardner, G., Pescevitiz, M., Halloran, P., ... Burdick, J. (1998). Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab triple therapy study group. The New England Journal of Medicine, 338, 161–165.

Walther, M., Tongren, J. E., Andrews, L., Korbel, D., King, E., Fletcher, H., ... Hill, A. V. (2005). Upregulation of TGF-beta, FOXP3, and CD4+CD25+ regulatory T cells correlates with more rapid parasite growth in human malaria infection. Immunity, 23, 287–296.

Wang, X., Snojndler, M., Gao, Y., Wan, Y., & Snojndler, H. (2016). Immune homeostatic macrophages programmed by the bacterial surface protein NhhA potentiate nasopharyngeal carriage of Neisseria meningitidis. MBio, 7, e01670–e01615.

Wang, S. M., Tsai, M. H., Lei, H. Y., Wang, J. R., & Liu, C. C. (2012). The regulatory T cells in anti-influenza antibody response post influenza vaccination. Human Vaccines & Immunotherapeutics, 8, 1243–1249.

Weiss, L., Donkova-Petrini, V., Caccavelli, L., Balbo, M., Carbonneil, C., & Levy, Y. (2004). Human immunodeficiency virus-driven expansion of CD4+CD25+ regulatory T cells, which suppress HIV-specific CD4 T-cell responses in HIV-infected patients. Blood, 104, 3249–3256.

Wiesner, D. L., Smith, K. D., Kotov, D. I., Nielsen, J. N., Bohjanen, P. R., & Nielsen, K. (2016). Regulatory T cell induction and retention in the lungs drives suppression of detrimental type 2 Th cells during pulmonary Cryptococcal infection. Journal of Immunology, 196, 365–374.

Yang, B. H., Hagemann, S., Mamareli, P., Lauer, U., Hoffmann, U., Beckstette, M., ... Lochner, M. (2016). Foxp3(+) T cells expressing RORγt represent a stable regulatory T-cell effector lineage with enhanced suppressive capacity during intestinal inflammation. Mucosal Immunology, 9, 444–457.

Zhang, Q., Leong, S. C., McNamara, P. S., Mubarak, A., Malley, R., & Finn, A. (2011). Characterisation of regulatory T cells in nasal associated lymphoid tissue in children: Relationships with pneumococcal colonisation. PLoS Pathogens, 7. e1002175.